QURE

19.3504.35%
WA

Walid Abi-Saab

Chief Medical Officer

Dr. Walid Abi-Saab, MD, serves as Chief Medical Officer of uniQure N.V. since June 26, 2023. He joined uniQure N.V. on June 26, 2023. He had been Chief Medical Officer of Galapagos NV since March 1, 2017 until December 31, 2022 and served as its Member of Management Board until December 31, 2022. Dr. Abi-Saab was with Shire Pharmaceuticals where he held various clinical development leadership roles, served as Group Vice President, Global Clinical Development - Therapeutic Area Head, Gastro-intestinal, Endocrinology and Metabolism. He led clinical development activities at Novartis, Abbott Laboratories and Pfizer, addressing a wide range of therapeutic areas and leading teams throughout the clinical development process. Under his leadership, more than 30 molecules have advanced through clinical development leading to several approvals in the US, EU and Canada. Prior to his pharma roles, he was Assistant Professor of Psychiatry and Neurosurgery at Yale University Medical School, where he Headed their Schizophrenia Research at the Clinical Neuroscience Research Unit and the Neurosurgery Epilepsy Microdialysis Research Program. He completed a Psychiatry residency training and a Neuroscience Research Fellowship at Yale University Medical School in New Haven, Connecticut. He holds an MD degree from Universit? Saint Joseph in Beirut, Lebanon. He obtained his bachelors degree in biology from the American University of Beirut, Lebanon.

Positions